- Home
- Publications
- Publication Search
- Publication Details
Title
Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia
Authors
Keywords
-
Journal
Frontiers in Neuroscience
Volume 15, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-04-12
DOI
10.3389/fnins.2021.641047
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glutamate Hypothesis in Schizophrenia
- (2019) Yota Uno et al. PSYCHIATRY AND CLINICAL NEUROSCIENCES
- Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials
- (2019) Chun-Hung Chang et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia
- (2019) Jochen Kindler et al. MOLECULAR PSYCHIATRY
- Linking phencyclidine intoxication to the tryptophan-kynurenine pathway: Therapeutic implications for schizophrenia
- (2019) Hidetsugu Fujigaki et al. NEUROCHEMISTRY INTERNATIONAL
- D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression?
- (2019) Mary-Anne B. MacKay et al. Frontiers in Psychiatry
- NMDAR Hypofunction Animal Models of Schizophrenia
- (2019) Gloria Lee et al. Frontiers in Molecular Neuroscience
- Sex influences in the preventive effects of N-acetylcysteine in a two-hit animal model of schizophrenia
- (2019) Aline Santos Monte et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Cognition and Reward Circuits in Schizophrenia: Synergistic, Not Separate
- (2019) A.J. Robison et al. BIOLOGICAL PSYCHIATRY
- Deletion of Glycogen Synthase Kinase-3β in D2 Receptor-Positive Neurons Ameliorates Cognitive Impairment via N-Methyl-D-Aspartate Receptor-Dependent Synaptic Plasticity
- (2019) Yan-Chun Li et al. BIOLOGICAL PSYCHIATRY
- Novel Treatment for the hardest-to-treat Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant
- (2019) Chieh-Hsin Lin et al. CURRENT DRUG TARGETS
- Does kynurenic acid act on nicotinic receptors? An assessment of the evidence
- (2019) Trevor W. Stone JOURNAL OF NEUROCHEMISTRY
- The origin of NMDA receptor hypofunction in schizophrenia
- (2019) Kazu Nakazawa et al. PHARMACOLOGY & THERAPEUTICS
- Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia
- (2019) Grant McQueen et al. PSYCHOPHARMACOLOGY
- ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis
- (2019) S. M. Cotton et al. Trials
- Synaptic deficits in iPSC-derived cortical interneurons in schizophrenia are mediated by NLGN2 and rescued by N-acetylcysteine
- (2019) Annie Kathuria et al. Translational Psychiatry
- Potential mechanisms for phencyclidine/ketamine-induced brain structural alterations and behavioral consequences
- (2019) Cheng Wang et al. NEUROTOXICOLOGY
- N -acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials
- (2018) W. Zheng et al. ACTA PSYCHIATRICA SCANDINAVICA
- Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects
- (2018) Deepak Cyril D’Souza et al. BIOLOGICAL PSYCHIATRY
- The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia
- (2018) Branden J Stansley et al. CURRENT OPINION IN PHARMACOLOGY
- Mechanisms of ketamine action as an antidepressant
- (2018) P Zanos et al. MOLECULAR PSYCHIATRY
- Therapeutic effect of adjunctive N -acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial
- (2018) Zahra Sepehrmanesh et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Rare loss of function mutations in N-methyl-d-aspartate glutamate receptors and their contributions to schizophrenia susceptibility
- (2018) Yanjie Yu et al. Translational Psychiatry
- Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient
- (2018) Emmanuel Pinard et al. CHIMIA
- Drug discovery strategies and the preclinical development of D-amino-acid oxidase inhibitors as antipsychotic therapies
- (2018) Bence Szilágyi et al. Expert Opinion on Drug Discovery
- Memory and cognition in schizophrenia
- (2018) J. Y. Guo et al. MOLECULAR PSYCHIATRY
- Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders
- (2018) Alan Breier et al. SCHIZOPHRENIA RESEARCH
- Effect of Damaging Rare Mutations in Synapse-Related Gene Sets on Response to Short-term Antipsychotic Medication in Chinese Patients With Schizophrenia
- (2018) Qiang Wang et al. JAMA Psychiatry
- Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study
- (2017) Viktoria Moschetti et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans
- (2017) Stephanie Thiebes et al. JOURNAL OF PSYCHIATRY & NEUROSCIENCE
- Assessment of the Target Engagement and d-Serine Biomarker Profiles of the d-Amino Acid Oxidase Inhibitors Sodium Benzoate and PGM030756
- (2017) Eimear Howley et al. NEUROCHEMICAL RESEARCH
- Oral administration of a specific kynurenic acid synthesis (KAT II) inhibitor attenuates evoked glutamate release in rat prefrontal cortex
- (2017) D.M. Bortz et al. NEUROPHARMACOLOGY
- Apathy in schizophrenia: A review of neuropsychological and neuroanatomical studies
- (2017) Catherine Bortolon et al. NEUROPSYCHOLOGIA
- The influence of the glutamatergic system on cognition in schizophrenia: A systematic review
- (2017) Elizabeth H.X. Thomas et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis
- (2017) Philippe Conus et al. SCHIZOPHRENIA BULLETIN
- Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis
- (2017) Eric Plitman et al. SCHIZOPHRENIA BULLETIN
- Effects of Augmenting N-Methyl-D-Aspartate Receptor Signaling on Working Memory and Experience-Dependent Plasticity in Schizophrenia: An Exploratory Study Using Acute d-cycloserine
- (2017) Jennifer K Forsyth et al. SCHIZOPHRENIA BULLETIN
- Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia
- (2017) Eduardo Dunayevich et al. SCHIZOPHRENIA RESEARCH
- The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial
- (2017) Alex Ryan et al. Trials
- Expression of D-Amino Acid Oxidase (DAO/DAAO) and D-Amino Acid Oxidase Activator (DAOA/G72) during Development and Aging in the Human Post-mortem Brain
- (2017) Vinita Jagannath et al. Frontiers in Neuroanatomy
- Targeting metabotropic glutamate receptors for novel treatments of schizophrenia
- (2017) James Maksymetz et al. Molecular Brain
- Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2017) Chieh-Hsin Lin et al. BIOLOGICAL PSYCHIATRY
- The effects of glycine on auditory mismatch negativity in schizophrenia
- (2017) Lisa-Marie Greenwood et al. SCHIZOPHRENIA RESEARCH
- Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms
- (2017) Joshua T. Kantrowitz et al. SCHIZOPHRENIA RESEARCH
- Mismatch negativity as a biomarker of theta band oscillatory dysfunction in schizophrenia
- (2017) Daniel C. Javitt et al. SCHIZOPHRENIA RESEARCH
- Treatment in early psychosis with N-acetyl-cysteine for 6 months improves low-level auditory processing: Pilot study
- (2017) Chrysa Retsa et al. SCHIZOPHRENIA RESEARCH
- A predictive coding account of MMN reduction in schizophrenia
- (2016) Catherine Wacongne BIOLOGICAL PSYCHOLOGY
- D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity
- (2016) Donald Goff Current Neuropharmacology
- The dopamine D3 receptor, a quarter century later
- (2016) Pierre Sokoloff et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects
- (2016) Alessandro Minarini et al. Expert Opinion on Drug Metabolism & Toxicology
- Sulforaphane Prevents Methylmercury-Induced Oxidative Damage and Excitotoxicity Through Activation of the Nrf2-ARE Pathway
- (2016) Shu Feng et al. MOLECULAR NEUROBIOLOGY
- Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis
- (2016) Giles E. Hardingham et al. NATURE REVIEWS NEUROSCIENCE
- Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2
- (2016) L. Lundström et al. NEUROPHARMACOLOGY
- An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia
- (2016) Darrick T Balu et al. NEUROPSYCHOPHARMACOLOGY
- Anti-NMDA receptor encephalitis, autoimmunity, and psychosis
- (2016) Matthew S. Kayser et al. SCHIZOPHRENIA RESEARCH
- Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine
- (2015) Akiko Matsuura et al. ACTA NEUROPSYCHIATRICA
- Long-term potentiation and the role of N -methyl- d -aspartate receptors
- (2015) Arturas Volianskis et al. BRAIN RESEARCH
- Kynurenine Aminotransferases and the Prospects of Inhibitors for the Treatment of Schizophrenia
- (2015) Gayan Jayawickrama et al. CURRENT MEDICINAL CHEMISTRY
- The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond
- (2015) Darrick T Balu et al. CURRENT OPINION IN PHARMACOLOGY
- Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials
- (2015) Y Iwata et al. MOLECULAR PSYCHIATRY
- Biased mGlu 5 -Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu 5 Modulation of NMDAR Currents
- (2015) Jerri M. Rook et al. NEURON
- Augmenting NMDA receptor signaling boosts experience-dependent neuroplasticity in the adult human brain
- (2015) Jennifer K. Forsyth et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment
- (2015) Amr Ellaithy et al. TRENDS IN NEUROSCIENCES
- Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia
- (2015) Susana Conde-Ceide et al. ACS Medicinal Chemistry Letters
- Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine
- (2015) Akiko Matsuura et al. ACTA NEUROPSYCHIATRICA
- An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia
- (2015) Akihiro Shiina et al. Clinical Psychopharmacology and Neuroscience
- Dietary Intake of Sulforaphane-Rich Broccoli Sprout Extracts during Juvenile and Adolescence Can Prevent Phencyclidine-Induced Cognitive Deficits at Adulthood
- (2015) Yumi Shirai et al. PLoS One
- A Randomized, Double-Blind Evaluation ofd-Cycloserine or Alprazolam Combined With Virtual Reality Exposure Therapy for Posttraumatic Stress Disorder in Iraq and Afghanistan War Veterans
- (2014) Barbara Olasov Rothbaum et al. AMERICAN JOURNAL OF PSYCHIATRY
- A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia – Results from the CandleLyte study
- (2014) D. Bugarski-Kirola et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- The Selective Glycine Uptake Inhibitor Org 25935 as an Adjunctive Treatment to Atypical Antipsychotics in Predominant Persistent Negative Symptoms of Schizophrenia
- (2014) Joep H. Schoemaker et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- The neurobiology and treatment of first-episode schizophrenia
- (2014) R S Kahn et al. MOLECULAR PSYCHIATRY
- Extrasynaptic NMDA Receptor Involvement in Central Nervous System Disorders
- (2014) Matthew P. Parsons et al. NEURON
- d-Cycloserine augmentation of cognitive remediation in schizophrenia
- (2014) Christopher K. Cain et al. SCHIZOPHRENIA RESEARCH
- Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia
- (2014) Daniel Umbricht et al. JAMA Psychiatry
- Nutritional strategies to modulate inflammation and oxidative stress pathways via activation of the master antioxidant switch Nrf2
- (2013) Ludmila F.M.F. Cardozo et al. BIOCHIMIE
- Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy
- (2013) Kee-Hong Choi et al. BRITISH JOURNAL OF PSYCHIATRY
- N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia
- (2013) Mehdi Farokhnia et al. CLINICAL NEUROPHARMACOLOGY
- SNARE proteins are essential in the potentiation of NMDA receptors by group II metabotropic glutamate receptors
- (2013) Jia Cheng et al. JOURNAL OF PHYSIOLOGY-LONDON
- Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: An updated meta-analysis of randomized placebo-controlled trials
- (2013) Yuki Matsuda et al. JOURNAL OF PSYCHIATRIC RESEARCH
- NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
- (2013) Pierre Paoletti et al. NATURE REVIEWS NEUROSCIENCE
- A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia
- (2013) Marina Ermilov et al. SCHIZOPHRENIA RESEARCH
- Group II metabotropic glutamate receptors modify N-methyl-D-aspartate receptors via Src kinase
- (2013) Catherine Trepanier et al. Scientific Reports
- Add-on Treatment of Benzoate for Schizophrenia
- (2013) Hsien-Yuan Lane et al. JAMA Psychiatry
- Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: Facts and challenges
- (2012) Edson X. Albuquerque et al. BIOCHEMICAL PHARMACOLOGY
- Synaptic and Extrasynaptic NMDA Receptors Are Gated by Different Endogenous Coagonists
- (2012) Thomas Papouin et al. CELL
- A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease
- (2012) Katsuya Harada et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A Multicenter, Add-On Randomized Controlled Trial of Low-Dosed-Serine for Negative and Cognitive Symptoms of Schizophrenia
- (2012) Mark Weiser et al. JOURNAL OF CLINICAL PSYCHIATRY
- Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia
- (2012) Natalie Matosin et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Glutathione Precursor N-Acetyl-Cysteine Modulates EEG Synchronization in Schizophrenia Patients: A Double-Blind, Randomized, Placebo-Controlled Trial
- (2012) Cristian Carmeli et al. PLoS One
- NMDA Receptor and Schizophrenia: A Brief History
- (2012) J. T. Coyle SCHIZOPHRENIA BULLETIN
- Regulation of the Keap1/Nrf2 system by chemopreventive sulforaphane: implications of posttranslational modifications
- (2011) Young-Sam Keum Annals of the New York Academy of Sciences
- Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia
- (2011) Surendra P. Singh et al. CNS DRUGS
- Glycine Transporter-1: A New Potential Therapeutic Target for Schizophrenia
- (2011) Kenji Hashimoto et al. CURRENT PHARMACEUTICAL DESIGN
- A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia
- (2011) Bruce J. Kinon et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Modelling schizophrenia using human induced pluripotent stem cells
- (2011) Kristen J. Brennand et al. NATURE
- Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia
- (2011) Matthew J. Fell et al. NEUROPHARMACOLOGY
- d-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia
- (2011) Jennifer D. Gottlieb et al. SCHIZOPHRENIA RESEARCH
- Cognition in schizophrenia: core psychological and neural mechanisms
- (2011) Deanna M. Barch et al. TRENDS IN COGNITIVE SCIENCES
- Targeting glutamate synapses in schizophrenia
- (2011) Julie R. Field et al. TRENDS IN MOLECULAR MEDICINE
- Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia
- (2011) David A. Lewis et al. TRENDS IN NEUROSCIENCES
- Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis
- (2010) Guochuan Tsai et al. CURRENT PHARMACEUTICAL DESIGN
- Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition
- (2010) Gerard J. Marek EUROPEAN JOURNAL OF PHARMACOLOGY
- Disease-relevant autoantibodies in first episode schizophrenia
- (2010) Michael S. Zandi et al. JOURNAL OF NEUROLOGY
- Redox Dysregulation Affects the Ventral But Not Dorsal Hippocampus: Impairment of Parvalbumin Neurons, Gamma Oscillations, and Related Behaviors
- (2010) P. Steullet et al. JOURNAL OF NEUROSCIENCE
- Structural Determinants of D-Cycloserine Efficacy at the NR1/NR2C NMDA Receptors
- (2010) S. M. Dravid et al. JOURNAL OF NEUROSCIENCE
- Long-term potentiation depends on release of d-serine from astrocytes
- (2010) Christian Henneberger et al. NATURE
- Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders
- (2010) Giles E. Hardingham et al. NATURE REVIEWS NEUROSCIENCE
- NMDA Receptor Ablation on Parvalbumin-Positive Interneurons Impairs Hippocampal Synchrony, Spatial Representations, and Working Memory
- (2010) Tatiana Korotkova et al. NEURON
- High dose D-serine in the treatment of schizophrenia
- (2010) Joshua T. Kantrowitz et al. SCHIZOPHRENIA RESEARCH
- Evaluation of NMDA receptor models of schizophrenia: Divergences in the behavioral effects of sub-chronic PCP and MK-801
- (2009) Alexandre Seillier et al. BEHAVIOURAL BRAIN RESEARCH
- A randomized, double-blind, placebo-controlled comparison study of sarcosine ( N-methylglycine) and d-serine add-on treatment for schizophrenia
- (2009) Hsien-Yuan Lane et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Activation of Glycogen Synthase Kinase-3 Is Required for Hyperdopamine and D2 Receptor-Mediated Inhibition of Synaptic NMDA Receptor Function in the Rat Prefrontal Cortex
- (2009) Y.-C. Li et al. JOURNAL OF NEUROSCIENCE
- Schizophrenia
- (2009) Jim van Os et al. LANCET
- Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes
- (2009) Juan E Belforte et al. NATURE NEUROSCIENCE
- N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial
- (2008) Michael Berk et al. BIOLOGICAL PSYCHIATRY
- d-Amino acids in the brain: d-serine in neurotransmission and neurodegeneration
- (2008) Herman Wolosker et al. FEBS Journal
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
- (2008) Stefan Leucht et al. LANCET
- Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study
- (2008) D GOFF et al. SCHIZOPHRENIA RESEARCH
- Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study
- (2007) Hsien-Yuan Lane et al. BIOLOGICAL PSYCHIATRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started